Autocrine and paracrine signaling leading to stimulation of tumor cell growth is a common theme in human cancers. In addition to polypeptide growth factors such as EGF family members which signal through receptor tyrosine kinases, accumulating evidence supports the autocrine and paracrine involvement of speci®c neuropeptides with de®ned physiologic actions as neurotransmitters and gut hormones in lung, gastric, colorectal, pancreatic and prostatic cancers. These neuropeptides, including gastrin-releasing peptide, neuromedin B, neurotensin, gastrin, cholecystokinin and arginine vasopressin bind seven transmembrane-spanning receptors that couple to heterotrimeric G proteins. Studies with human small cell lung cancer (SCLC) cells support a requirement for balanced signaling through G q and G 12/13 proteins leading to intracellular Ca 2+ mobilization, PKC activation and regulation of the ERK and JNK MAP kinase pathways. While speci®c neuropeptide antagonists oer promise for interrupting the single neuropeptide autocrine systems operating in pancreatic and prostatic cancers, SCLC is exempli®ed by multiple, redundant neuropeptide autocrine systems such that tumor growth cannot be inhibited with a single speci®c antagonist. However, a novel class of neuropeptide derivatives based on the substance P sequence have been de®ned that exhibit broad speci®city for neuropeptide receptors and induce apoptosis in SCLC by functioning as biased agonists that stimulate discordant signal transduction. Thus, interruption of autocrine and paracrine neuropeptide signaling with speci®c antagonists or broad-spectrum biased agonists oer promising new therapeutic approaches to the treatment of human cancers. Oncogene (2001) 20, 1563 ± 1569.
Introduction
Neuropeptides function peripherally as paracrine and endocrine factors to regulate diverse physiologic processes and act as neurotransmitters or neuromodulators in the nervous system. In the large majority of cases, the receptors which mediate signaling by neuropeptides are members of the superfamily of G protein-coupled, seven membrane-spanning receptors (Burbach and Meijer, 1992) . In this review, speci®c examples where physiologic functions of selected neuropeptide families are subverted to roles in tumorigenesis and hyperplastic growth are explored. The precise neuropeptide receptor subtypes and the dominant intracellular signaling pathways that mediate the various proliferative responses are reviewed and the emerging utilities of both speci®c and broad-spectrum neuropeptide antagonists as therapeutics for human cancers are considered.
Neuropeptides with putative autocrine or paracrine involvement in human cancers
While a large number of peptide hormones have been identi®ed with putative roles as growth factors in human cancer, this review will restrict its focus to the evidence supporting the autocrine and paracrine involvement of the bombesin-related peptides, gastrin, cholecystokinin, neurotensin and arginine vasopressin in human cancer. Physiologically, each of these peptides ful®lls dual functions; as a neurotransmitter or neuromodulator in the nervous system and as a hormone or endocrine factor in the periphery. A brief overview of the normal functions of the dierent peptides and their receptors is presented below as well as the evidence for their autocrine and paracrine involvement in speci®c human cancers.
Bombesin-like peptides
The prototypical neuropeptides in this family, bombesin and ranatensin, were ®rst isolated from amphibian skin and led to the subsequent identi®cation of the mammalian homologues, gastrin-releasing peptide (GRP) and neuromedin B (NMB), respectively (reviewed in Battey and Wada, 1991; Ohki-Hamazaki, 2000) . In the periphery, GRP and NMB control a wide spectrum of actions including smooth muscle contraction and exocrine and endocrine secretion. GRP is, in fact, named for its ability to stimulate gastrin release from gastrin (G) cells in the antral mucosa. Acting at the central nervous system, these peptides regulate food intake, body temperature and glucose levels as well as certain behavioral responses. Seven membrane-spanning receptors exhibit-ing selectivity for GRP or NMB have been identi®ed through molecular cloning approaches (reviewed in Battey and Wada, 1991; Ohki-Hamazaki, 2000) . In addition, a distinct receptor referred to as bombesin receptor subtype-3 (BRS-3) with extensive homology to the GRP and NMB receptors has been cloned, for which the endogenous ligand remains unde®ned (Fathi et al., 1993; Gorbulev et al., 1992) . Interestingly, mice in which the BRS-3 gene has been disrupted develop multiple metabolic defects and mild obesity, indicating that BRS-3 and its unde®ned ligand also regulate important endocrine and metabolic processes (OhkiHamazaki et al., 1997) .
The bombesin-like peptides, GRP and NMB, were among the ®rst neuropeptides to be implicated as autocrine growth factors in lung cancer cells. In small cell lung cancer (SCLC) cells, GRP (Cuttitta et al., 1985; Moody et al., 1981) and NMB (Cardona et al., 1991) are widely synthesized and secreted into the medium. In addition, the majority of SCLC cells express the mRNA for one or more of the bombesinlike receptors (Corjay et al., 1991; Fathi et al., 1993; Toi-Scott et al., 1996) . The functionality of the GRP and NMB receptors expressed on SCLC cells as measured by intracellular Ca 2+ mobilization in response to applied GRP or NMB has also been established (Bunn et al., 1992; Corjay et al., 1991; Moody et al., 1992; Woll and Rozengurt, 1989) . The ability of bombesin-like peptide antagonists (Mahmoud et al., 1991) or neutralizing antibodies (Cuttitta et al., 1985) to reduce the growth of some cultured SCLC cell lines provides evidence for bombesin-like peptides as autocrine growth factors in SCLC. However, as will become clear in this review, SCLC is an example of a cancer where multiple, variably-expressed neuropeptide autocrine systems operate in a redundant fashion and their simultaneous disruption will most likely be required for eective inhibition of cell growth.
Normal prostate tissue and a substantial proportion (*70%) of primary and metastatic prostatic tumors contain a dispersed subpopulation of neuroendocrine cells that appear to expand in prostate cancers as they become androgen-independent (Aprikian et al., 1998; Nelson and Carducci, 2000) . These neuroendocrine cells express a variety of bioactive neuropeptides including GRP. A number of studies document the elevated expression of GRP receptors in prostate cancer specimens (Bartholdi et al., 1998; Markwalder and Reubi, 1999; Sun et al., 2000a) and on cultured prostatic cancer cell lines (Aprikian et al., 1996) , supporting a paracrine role for GRP in prostate cancer progression.
While SCLC and prostate cancer are the best characterized human tumors where bombesin-like peptides are likely to function as autocrine or paracrine growth factors, the literature indicates the co-expression of GRP and GRP receptors in colorectal samples (Chave et al., 2000) . Also, expression of all three bombesin-like peptide receptor subtypes has been noted in ovarian epithelial cancers although the expression of their neuropeptide ligands were not assessed (Sun et al., 2000b) . However, the ability of GRP antagonists to inhibit the growth of an ovarian carcinoma cell line (Chatzistamou et al., 2000) suggests that a GRP autocrine system may also function in ovarian carcinomas. Finally, both central and peripheral primitive neuroectodermal tumors (PNET) have been shown to express GRP (Fruhawald et al., 1998; Lawlor et al., 1998) and the in vitro growth of a peripheral PNET cell line was inhibited by a GRP receptor antagonist (Lawlor et al., 1998) .
Gastrin and cholecystokinin Gastrin and cholecystokinin (CCK) serve physiological functions as hormones in the gastrointestinal tract and as neuropeptides in the nervous system (reviewed in Wank, 1995 Wank, , 1998 . Gastrin and CCK are derived from distinct preprohormones, but are structurally similar peptides that share the same C-terminal ®ve amino acids, are aamidated at their C-termini and are partially sulfated on tyrosine. CCK is synthesized in neurons throughout the central and peripheral nervous system and in intestinal neuroendocrine cells (I cells) while gastrin peptides are expressed and released from the duodenum and gastric antrum (gastrin cells) as well as the pituitary. Two distinct receptors for gastrin and CCK have been identi®ed to date; the CCK-A receptor is highly selective for sulfated CCK, while the CCK-B receptor exhibits a similar high anity for both sulfated and nonsulfated CCK and gastrin (Wank, 1995 (Wank, , 1998 . CCK-A receptors are expressed on multiple cell types in the pancreas, stomach and intestine, but are also expressed in select areas of the central and peripheral nervous system. By contrast, the CCK-B receptors are predominantly expressed in the central nervous system in a pattern similar to CCK and on parietal cells and enterochroman-like (ECL) cells in the gastric mucosa.
In addition to regulating gastrointestinal hormone secretion, evidence indicates that gastrin and CCK exert mitogenic actions on speci®c cells in the gastric mucosa and pancreas, respectively. Hypergastrinemia resulting from pharmacological blockade of acid secretion from parietal cells leads to a modest, but stable increase in gastrin cell density. The ECL cells in the gastric mucosa also respond mitogenically to elevated gastrin levels except that their density steadily increases during hypergastrinemia and eventually may result in the formation of ECL cell carcinoids (Dockray, 1999; Sundler et al., 1991) . CCK via the CCK-A receptor mediates the pancreatic hyperplasia observed following the feeding of protease inhibitors or pancreaticobiliary diversion and CCK enhances the induction by carcinogens of acinar tumors in the pancreas (reviewed in Watanapa and Williamson, 1993) .
The potential role of gastrin and CCK as autocrine or paracrine factors in gastrointestinal cancers is controversial (reviewed in Baldwin, 1995, Baldwin and Shulke, 1998) . While the evidence indicates that most gastrointestinal carcinomas express and synthesize progastrin, con¯icting reports on the degree of gastrin amidation which is required for binding to the de®ned CCK-B receptor in cancer specimens and cell lines prevent a clear assignment of gastrin as an autocrine factor in gastrointestinal cancer. However, novel gastrin receptors unrelated to either CCK-A or CCK-B receptors that bind non-amidated gastrin peptides have been described and should be considered as potential mediators of autocrine and paracrine growth actions of gastrin peptides in gastrointestinal cancers (Baldwin and Shulke, 1998; Dockray, 1999) . By contrast, convincing evidence supports the involvement of a gastrin and CCK-B receptor autocrine system in the pathogenesis of human pancreatic carcinoma. Amidated gastrin was detected in the majority of pancreatic adenocarcinomas, but not in normal pancreatic tissue and the CCK-B receptor mRNA was expressed in all carcinomas. While the CCK-A receptor mRNA was also widely expressed in most of the tumor samples, neither amidated and sulfated CCK nor CCK precursors were expressed in the carcinomas or normal pancreatic tissues (Goetze et al., 2000; Weinberg et al., 1997) . Moreover, coexpression of gastrin and CCK-B receptors is observed in multiple cultured pancreatic carcinoma cell lines and growth of these cell lines is inhibited by CCK-B receptor antagonists and gastrin neutralizing antibodies (Blackmore and Hirst, 1992; Smith et al., 1994 Smith et al., , 1996 .
Evidence also exists to support the autocrine action of CCK and gastrin in SCLC. The CCK gene is expressed in cultured SCLC cells and the preproCCK is processed into bioactive, carboxyamidated CCK peptides (Geijer et al., 1990) . Gastrin mRNA was also frequently detected in SCLC (Reubi et al., 1997) . Moreover, both CCK-A (Sethi, 1993) and CCK-B receptors have been measured on SCLC cells (Reubi et al., 1997; Staley et al., 1990) and gastrin and CCK stimulate intracellular Ca 2+ mobilization Sethi et al., 1993; Staley et al., 1989) . As with GRP, the redundancy of neuropeptide autocrine systems in SCLC complicates the clear assignment of any particular neuropeptide to a dominant role in cellular transformation in SCLC.
Arginine vasopressin The neurohypophysial hormone arginine vasopressin (AVP) is a peripheral regulator of water excretion in the kidney, a potent vasoconstrictor and a neurotransmitter or neuromodulator in the central nervous system. The AVP peptide is derived from a large precursor encoding a signal peptide, the nine amino acid peptide hormone, a neurophysin polypeptide that serves as a hormone carrier and a C-terminal glycoprotein of unknown function (Ivell et al., 1983) . Three distinct AVP receptors (V 1 , V 2 and V 3 ) have been identi®ed through molecular cloning techniques (reviewed in Thibonnier et al., 1998) . The V 1 receptor is expressed in vascular smooth muscle cells and mediates the vasoconstrictor actions of AVP (Nemeno, 1998) , but is also expressed in many other tissues and is the major AVP receptor in the brain. By contrast, expression of the V 2 receptor is largely restricted to the renal medulla where it mediates the antidiuretic eect of AVP. The V 3 receptor was initially described in pituitary corticotroph cells where it potentiates the release of ACTH, but is expressed in many other cell types with functions that remain to be de®ned.
Similar to the bombesin-like peptides, a considerable percentage of cultured SCLC cells express (Gross et al., 1993; Sausville et al., 1985; Verbeeck et al., 1992) and secrete (Gross et al., 1993) AVP. Consistent with the in vitro production of AVP by SCLC cells, SCLC patients frequently present with elevated plasma AVP (Gross et al., 1993; North, 1991) which, via the renal V 2 receptor, leads to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), associated with plasma hyponatremia and hypoosmolality and urinary hyperosmolality (Gross et al., 1993; Hamilton et al., 1972) . As with the bombesin-like peptides and gastrin/CCK, AVP and the de®ned AVP receptors are frequently co-expressed in SCLC (North et al., 1998) , thereby establishing the potential for autocrine-stimulated growth. These observations coupled with ®ndings that many SCLC lines respond to exogenously-added AVP with intracellular Ca 2+ mobilization (Bunn et al., 1992; Hong and Moody, 1991; Woll and Rozengurt, 1989) and increased cloning eciency (Sethi and Rozengurt, 1991) suggest that AVP, like GRP, gastrin and CCK, may contribute to autocrine growth of SCLC.
Neurotensin The neuropeptide, neurotensin (NT), provides yet another example of a peptide that serves dual functions as a neurotransmitter or neuromodulator in the nervous system and a hormone in the periphery. Centrally, NT is a modulator of dopamine transmission and pituitary hormone secretion and exerts hypothermic and analgesic eects in the brain while it functions as a peripheral hormone in the digestive tract and cardiovascular system. Cloning eorts have de®ned two distinct receptors with seven membrane-spanning topography that are expressed in speci®c brain regions and the intestine as well as a novel receptor identical to sortilin (Vincent et al., 1999) . Evidence indicates that NT also serves as an autocrine growth factor in prostate cancer. NT receptors were detected in an androgen-independent prostatic carcinoma cell line and NT stimulated the growth of these cells, indicating that NT could contribute to the growth or survival of prostate tumor cells (Seethalakshmi et al., 1997) . In a separate study, withdrawal of androgen from an androgen-dependent prostate cancer cell line increased the production and secretion of NT and the cell became mitogenicallyresponsive to NT (Sehgal et al., 1994) . Finally, NT is produced and secreted by SCLC cells (Davis et al., 1991; Moody et al., 1985) and SCLC cells respond to exogenously-added NT (Bunn et al., 1992; Sethi and Rozengurt, 1991; Seuerlein and Rozengurt, 1996; Woll and Rozengurt, 1989) , indicating that this neuropeptide may contribute along with the other neuropeptide families to the growth of SCLC.
Thus, evidence supports the involvement of diverse neuropeptide families as growth factors in human cancers. In the case of prostatic and pancreatic carcinomas, the candidate neuropeptides, GRP and gastrin, exert physiological roles in the tissues from which the cancers arise, indicating that the normal function of the neuropeptides has been subverted to actions in cellular transformation. The molecular alterations that may allow these peptides to function as growth factors in the cancer cells that arise from the respective tissues are not completely clear, although increased density of bombesin binding sites and GRP mRNA expression have been noted in prostatic carcinomas (Bartholdi et al., 1998; Markwalder and Reubi, 1999) . While CCK-B receptors are expressed in both normal pancreas and in pancreatic carcinomas, the majority of pancreatic carcinomas synthesized amidated gastrin but the normal pancreatic tissue expressed only trace amounts of poorly processed progastrin (Goetze et al., 2000) . Thus, a predicted result of increased receptor density in prostatic carcinomas or increased ligand production in pancreatic cancers would be an enhanced magnitude and/or duration of signaling in the evolving cancer cell. In a similar manner, ECL carcinoids in the stomach arise when local levels of gastrin, which serves as a growth factor for ECL cells, are chronically increased (Dockray, 1999; Sundler et al., 1991) .
The pulmonary precursor of SCLC and the regulatory mechanisms that result in the induction of the extensive array of neuropeptides and their cognate receptors remain poorly understood. While the existence of pulmonary neuroendocrine cells that synthesize GRP has been documented in normal and diseased lung (Miller, 1989) , these cells are generally not considered to be the cell of origin for SCLC. A more likely possibility is that induction of a regulatory mechanism(s) resulting in ectopic expression of a large number of neuroendocrine genes occurs during the selective steps that eventually result in small cell lung cancers. Several laboratories have employed the 5'-¯anking promoter regions of the AVP, GRP and the pro-opiomelanocortin genes to begin to de®ne the regulatory mechanisms that may mediate the general induction of neuroendocrine gene expression in SCLC (Coulson et al., 1999a,b; Markowitz et al., 1988; Nagalla and Spindel, 1994; Picon et al., 1995) . The ®ndings suggest that regulation of these genes will be complex and involve the modulation of repressors and enhancers as well as tissue-speci®c factors.
Signal pathways mediating neuropeptide-stimulated cellular transformation
Molecular cloning of receptors for the dierent neuropeptides described above reveals their membership in the superfamily of heterotrimeric G proteincoupled, seven transmembrane-spanning receptors. Moreover, analysis of signaling by the many neuropeptide receptors expressed in SCLC cells highlights their general ability to stimulate intracellular Ca 2+ mobilization (Bunn et al., 1992; Woll and Rozengurt, 1989) . Increased intracellular Ca 2+ concentrations are mediated by receptor interaction with G q proteins and the subsequent activation of phospholipase Cb (PLCb), which generates inositol trisphosphate (IP 3 ), a stimulatory ligand for endoplasmic reticulum Ca 2+ channels (Figure 1 and Dhanasekaran et al., 1995) . The targets of increased cellular Ca 2+ are poorly de®ned in SCLC cells, but are likely to include Ca 2+ / calmodulin-dependent protein kinases. Increased cellular Ca 2+ also integrates with diacylglycerol (DAG) generated by PLCb activity to stimulate protein kinase C (PKC) which, in many cells including SCLC cells (Seuerlein and Rozengurt, 1996) , serves as a proximal, neuropeptide-stimulated regulator of the protein kinase cascade leading to activation of the extracellular signal-regulated kinase (ERK) members of the mitogen-activated protein (MAP) kinase family (see Figure  1 and Schonwasser et al., 1998) . PKC has also been shown to mediate the activation of protein kinase D (PKD)/PKCm by neuropeptides in Swiss 3T3 cells and SCLC cells (Paolucci and Rozengurt, 1999; Zugaza et al., 1997) . The putative targets of PKD/PKCm in Figure 1 Signal pathways regulated by neuropeptide receptors. A prototypical neuropeptide receptor is depicted that couples to the indicated signaling pathways through G q and G 12,13 proteins. Abbreviations: PLCb, phospholipase Cb; PIP 2 , phosphatidylinositol-bisphosphate; IP 3 , inositol trisphosphate; DAG, diacylglycerol; PKC, protein kinase C; PKD, protein kinase D/PKCm; ERK, extracellular signal-regulated kinase; MEK, Mitogenactivated protein-ERK kinase; MEKK, MEK kinase; MKK, mitogen-activated protein kinase kinase; JNK, cJun N-terminal kinase; GEF, guanine nucleotide exchange factor. The positioning of the cytosolic tyrosine kinases, Src and Tec/Bmx, as direct eectors of G 12 and G 13 proteins that mediate Rho activation of the JNK pathway and the actin cytoskeleton is not intended neuropeptide-responsive cells and their role in cell growth and transformation remain to be de®ned. In addition to G q proteins, biochemical evidence indicates that neuropeptide receptors interact with G 12 and G 13 proteins (Barr et al., 1997; Jian et al., 1999; Wittau et al., 2000) , leading to the activation of the Ras and Rho family of monomeric G proteins (Collins et al., 1996; Wadsworth et al., 1997) and regulation of the cJun Nterminal kinase (JNK) members of the MAP kinase family (Heasley et al., 1996a,b; Higashita et al., 1997; Vara Prasad et al., 1995) as well as the reorganization of the actin cytoskeleton (Buhl et al., 1995; Gohla et al., 1999) . Identi®cation of the eectors that mediate these actions of G 12 and G 13 is an active area of investigation, and studies indicate roles for Rho family guanine nucleotide exchange factors (Kozasa et al., 1998) and Src and Tec/Bmx-family of tyrosine kinases (Mao et al., 1998; Nagao et al., 1999) upstream of JNK and cytoskeletal regulation. As depicted in Figure 1 , the Ca 2+ /calmodulin-dependent protein kinases, ERKs and JNKs are predicted to converge on transcription factors that control gene expression related to mitogenesis and cellular transformation. Thus, neuropeptide receptors couple to G q , G 12 and G 13 proteins which yield balanced signaling of Ca 2+ mobilization and ERK and JNK activation (Figure 1) .
Accumulating evidence suggests that G q proteins and PLCb exert dominant eects in signal transduction of SCLC cell growth. Expression of GTPasede®cient forms of Ga q proteins in SCLC lines induces desensitization of neuropeptide-stimulated Ca 2+ mobilization and increased basal JNK activity (Heasley et al., 1996a) . This paradoxical inhibition of Ca 2+ mobilization by constitutively activated Ga q proteins appears to arise by way of a compensatory down-regulation of IP 3 -liganded Ca 2+ channels in the endoplasmic reticulum (Lobaugh et al., 1996; Quick et al., 1996) . The resulting discordant signaling relative to the balanced signaling initiated by neuropeptide receptors is hypothesized to result in the marked reduction in SCLC cell growth that was observed (Heasley et al., 1996a) . In another study, expression of a catalytically-inactive form of PLCb in SCLC cells which retains the sequences that interact with Ga q signi®cantly inhibited basal PKC activity and receptor-stimulated phosphatidylinositol hydrolysis, Ca 2+ mobilization and ERK activation, but not JNK activation (Beekman et al., 1998) . Importantly, anchorage-independent cell growth was markedly blunted. These ®ndings together with studies showing strong SCLC cell growth reduction by inhibitors of PLCb (Strassheim et al., 2000) , PKC (Seuerlein and Rozengurt, 1996) and MEK (Seuerlein and Rozengurt, 1996) support the requirement for balanced signaling through G q proteins, PLCb, PKC, ERKs and Ca 2+ mobilization in neuropeptide-stimulated growth of SCLC cells. However, the requirement for G 12 and G 13 -regulated pathways including JNK activation and cytoskeletal regulation in neuropeptide-stimulated growth remain largely untested.
Substance P derivatives as novel therapeutics that stimulate apoptotic signaling through neuropeptide receptors
The identi®cation and characterization of substituted derivatives of the neuropeptide, substance P, that exhibited broad antagonist activity for a variety of neuropeptide receptors expressed on SCLC cells provide a novel approach to the disruption of multiple neuropeptide autocrine systems . Rozengurt and colleagues (Seckl et al., 1997; Rozengurt, 1988, 1990) have shown that speci®c substance P derivatives inhibit receptor-mediated Ca 2+ mobilization by multiple neuropeptides including AVP, CCK, GRP and NT and that the derivatives markedly reduce the in vitro growth of SCLC cells. Signi®cantly, the substance P derivatives also inhibit SCLC growth as xenografts in nude mice with little or no apparent toxicity (Everard et al., 1993; Langdon et al., 1992; Seckl et al., 1997) . Of importance are the ®ndings that the substance P derivatives induce apoptosis in lung cancer cell lines (Reeve and Bleehen, 1994; Rosati et al., 1998) and dierentially-inhibit receptor-mediated signaling of Ca 2+ mobilization and ERK activation (Mitchell et al., 1995) ] substance P, demonstrated that concentrations of peptide which block GRP-induced Ca 2+ mobilization cause activation of the JNK pathway and induce Rho-dependent cytoskeletal changes in Swiss 3T3 cells (Jarpe et al., 1998) . Induction of JNK activity by a dierent substance P derivative was also shown in SCLC cells (MacKinnon et al., 1999) . The ability of the substance P derivative to activate the JNK pathway was dependent upon the expression of a neuropeptide receptor (Jarpe et al., 1998) , revealing that the actions of these novel peptides are receptor-mediated. Based on their ability to selectively stimulate JNK activity and cytoskeletal changes, possibly through G 12 and G 13 , but not Ca 2+ mobilization through G q proteins, substance P derivatives have been hypothesized to represent a novel class of agonist referred to as biased agonists (Jarpe et al., 1998) . According to this hypothesis, substance P derivatives preferentially bind to and stabilize neuropeptide receptors in a conformational state that activates G 12 and G 13 proteins, but not G q proteins (Jarpe et al., 1998) . Thus, the substance P derivative oer a therapeutic approach to induce unbalanced, or discordant, signaling that is similar to what was previously accomplished in SCLC cells by retrovirus-mediated expression of constitutively active Ga q proteins or mutant PLCb proteins (Beekman et al., 1998; Heasley et al., 1996a) .
In conclusion, the substance P derivatives oer exciting promise as novel therapeutics for the receptor-mediated induction of apoptosis in cancer cells where neuropeptide autocrine and paracrine systems are involved. A search for shorter substance P derivatives or analogs with increased receptor anity or serum stability seems warranted and is, in fact, an ongoing focus of several laboratories (MacKinnon et al., 1999; Nyeki et al., 1998; Rosati et al., 1998; Woll and Rozengurt, 1990) . Ideally, a small nonpeptide molecule based on the structure of the substance P derivative that functions similarly, but avoids the problems associated with peptide synthesis and delivery, may represent an excellent therapeutic alone or in combination with existing chemotherapies for the treatment of human cancers involving neuropeptide receptor systems.
